PSMB8 and autoimmune disease: Since pharmacological inhibition of the immunoproteasomal active subunits LMP7/2 reduced inflammation and disease severity in experimental models of autoimmune diseases,9–12,14–18 we aimed to assess the effect of LMP7/2 inhibition on atherosclerosis.